The University of Chicago Header Logo

Connection

Ravi Salgia to Antineoplastic Combined Chemotherapy Protocols

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about Antineoplastic Combined Chemotherapy Protocols.
Ravi Salgia
Connection Strength
2.644
Antineoplastic Combined Chemotherapy Protocols
  1. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Invest New Drugs. 2017 06; 35(3):334-344.
    View in: PubMed
    Score: 0.291
  2. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer. 2017 03; 105:7-13.
    View in: PubMed
    Score: 0.287
  3. Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases. Tumori. 2013 Mar-Apr; 99(2):e73-6.
    View in: PubMed
    Score: 0.220
  4. 2-methoxyestradiol alters cell motility, migration, and adhesion. Blood. 2003 Jul 01; 102(1):289-96.
    View in: PubMed
    Score: 0.110
  5. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist. 2003; 8(1):69-75.
    View in: PubMed
    Score: 0.109
  6. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 08; 125(4):582-592.
    View in: PubMed
    Score: 0.097
  7. Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol. 2018 10; 41(10):963-966.
    View in: PubMed
    Score: 0.081
  8. Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone. Cancer Lett. 2018 12 01; 438:144-153.
    View in: PubMed
    Score: 0.081
  9. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. J Oncol Pract. 2018 09; 14(9):569-571.
    View in: PubMed
    Score: 0.080
  10. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
    View in: PubMed
    Score: 0.079
  11. Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract. 2018 06; 14(6):359-366.
    View in: PubMed
    Score: 0.079
  12. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
    View in: PubMed
    Score: 0.070
  13. Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol. 2016; 12(8):1045-58.
    View in: PubMed
    Score: 0.068
  14. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
    View in: PubMed
    Score: 0.066
  15. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6.
    View in: PubMed
    Score: 0.065
  16. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 2015 Aug; 26(8):1741-8.
    View in: PubMed
    Score: 0.064
  17. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol Cancer Ther. 2015 Feb; 14(2):461-9.
    View in: PubMed
    Score: 0.062
  18. Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report. Cancer. 1994 Oct 01; 74(7):1887-90.
    View in: PubMed
    Score: 0.061
  19. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.058
  20. EphB4 as a therapeutic target in mesothelioma. BMC Cancer. 2013 May 30; 13:269.
    View in: PubMed
    Score: 0.056
  21. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
    View in: PubMed
    Score: 0.054
  22. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer. 2012 Feb 28; 106(5):839-45.
    View in: PubMed
    Score: 0.051
  23. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.050
  24. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011 May; 6(5):942-6.
    View in: PubMed
    Score: 0.048
  25. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol. 2011 Apr; 6(4):786-9.
    View in: PubMed
    Score: 0.048
  26. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.042
  27. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.040
  28. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14.
    View in: PubMed
    Score: 0.040
  29. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008 Feb 20; 26(6):870-6.
    View in: PubMed
    Score: 0.039
  30. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
    View in: PubMed
    Score: 0.036
  31. A review of topoisomerase inhibition in lung cancer. Cancer Biol Ther. 2006 Dec; 5(12):1600-7.
    View in: PubMed
    Score: 0.036
  32. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol. 2001 Aug; 48(2):151-9.
    View in: PubMed
    Score: 0.025
  33. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185.
    View in: PubMed
    Score: 0.019
  34. Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma. J Clin Oncol. 2011 Jul 10; 29(20):e598-600.
    View in: PubMed
    Score: 0.012
  35. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55.
    View in: PubMed
    Score: 0.010
  36. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.